News - Financing risk management - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

Company news

When AI Starts "Guiding" Doctors: A New Assistant or a New Rival for Medical Professionals

Editor's NoteLast month, a doctor friend shared his confusion with me.A patient had just sat down when he thrust his phone in front of the doctor. The screen was densely packed with AI-generated "treatment recommendations"—from medication plans to lifestyle restrictions, covering every detail. With a hint of scrutiny, the patient asked: "Doctor, the AI says this medication has serious side effects. Your prescription is different. Could you double-check?"My friend was stunned. He had encountered patients who came with Baidu search results to "argue their case," but this was the first time a patient had brought an AI-generated "prescription" to "guide" his prescribing. And this is not an isolated incident.By 2026, AI is no longer a concept confined to laboratories. It has entered ICUs, tracing entire diagnostic and treatment journeys in 5 seconds. It has entered operating rooms, assisting screw placement with 0.1mm precision. It has e...

2026 - 04 - 02
22222

111111

2022 - 08 - 09
Yewei Medical Completes Nearly 100M RMB Series B to Strengthen Cardiovascular Surgery Footprint

Recently, Beijing Yewei Medical Technology Co., Ltd. ("Yewei Medical") announced the completion of a nearly 100 million RMB equity financing round. This round was led by Fenix Capital, with participation from Beishang Capital and Bohai Chuangfu, and Kaicheng Capital serving as the exclusive financial advisor.This marks Yewei Medical's second substantial financing round within the year, fully reflecting the capital market's strong recognition of the company's development trajectory. Supported by this financing, Yewei Medical will continue to comprehensively strengthen its R&D innovation and market penetration capabilities in cardiovascular surgery and other related fields, further solidifying its leading position.Founded in September 2021 and headquartered in Beijing, Yewei Medical leverages its founding team's extensive clinical experience to identify clinical needs while assessing current industry dynamics. The company is developing multiple global-first,...

2026 - 04 - 03
Monthly Health Digest | March 2026

PrefaceIn March, the industry grand event BIOCHINA 2026 kicked off in Suzhou. Mr. Zhu Pai, CEO of Efung Capital, was invited to attend and engaged in in-depth dialogue with industry peers on March 13 at the roundtable forum "LP-GP Ecosystem Encirclement: Synergizing Policy, Capital, and Innovation." Meanwhile, Efung Capital's portfolio companies also shone brightly at the conference, with companies such as IASO Bio making significant appearances, collectively showcasing the cutting-edge power of Chinese innovative drug companies.Beyond the conference, many of Efung Capital's portfolio companies are advancing steadily in their respective niche tracks, achieving key breakthroughs one after another and demonstrating vigorous development momentum. 01 Portfolio Company IPO and Financing Progress Huamei Haolian· AI Agent Reconstructing the Health Management Service EcosystemRecently, Huamei Haolian, a leading domestic AI-driven digital health s...

2026 - 03 - 31
China's First and World's First Recombinant Type A Botulinum Toxin Approved for Market

On March 25, the National Medical Products Administration (NMPA) officially announced that the Recombinant Type A Botulinum Toxin for Injection (National Drug Approval No. S20260019), developed by Chongqing Yuyan Pharmaceutical Co., Ltd. (a subsidiary of MingMed), has been approved for market. This is China's first and the world's first recombinant technology-produced Type A botulinum toxin, marking a core technological breakthrough in the botulinum toxin field for China and breaking the long-standing monopoly of imported products.Unlike traditional botulinum toxin fermentation processes using Clostridium botulinum, this product utilizes an E. coli expression system, completely eliminating the risks associated with pathogenic bacterial culture. The product is a 150kDa single-component neurotoxin, free from complex protein impurities, offering higher purity, lower immunogenicity, and significantly better clinical safety compared to traditional products.This approval is not only ...

2026 - 03 - 30
Frontier Biotechnologies Enters Exclusive License Agreement with GSK for siRNA Pipeline Products

Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New Drug (IND) application stage, while the other is a preclinical candidate.This agreement highlights the Company’s expertise in early-stage siRNA drug discovery and development, marking a significant milestone in advancing its global development strategy.Under the terms of the agreement, the Company will receive an upfront payment of $40 million. It is eligible to receive cumulative milestone payments totaling up to $963 million based on successful development, regulatory, and commercial achievements for the two programs, in addition to tiered royalties on global net sales of the two products.T...

2026 - 03 - 25

Copyright © 2018 2021.All Rights Reserved 粤公网安备44030402002338号 Rhino Cloud provides enterprise cloud services 犀牛云提供云计算服务